Ronnie Andrews

Mr. Andrews has over 35 years of experience in the Global Clinical and Molecular Diagnostics industry. Ronnie is currently the Managing Partner at pH Blueprint, an advisory firm that helps drive portfolio management, commercial go-to-market plans, organizational development, executive mentorship, product strategy, regulatory and reimbursement strategies for companies in the Biotech Tools and Molecular Diagnostics market.

Prior to joining pH Blueprint, Ronnie has served in several senior executive and C Suite roles such as CEO of Oncocyte, a Molecular Dx company located in Irvine CA. Previous leadership roles include President of the Genetic Sciences Division at Thermo Fisher Scientific following a merger with Life Technologies, where he served as President of the Medical Sciences Venture. During the merger, he oversaw the integration of Ion Torrent with the traditional genetic platform and content initiatives within Life Technologies to form a $2 billion division. Ronnie also served as Chief Executive Officer and Vice Chairman at Clarient Inc. from 2004 until 2010 when Clarient was purchased by GE Healthcare. At the close of the transaction, Ronnie oversaw the transition into GE Healthcare and established a strategic plan to expand GE’s presence in oncology. Ronnie currently serves as The Executive Chairman of SymBioSys, a cancer AI company, as well as serving on the Board of Directors of ASCO’s CancerlinQ, Quotient Dx, CellMax, and Precipio.